载阿霉素胶束抗胶质瘤体外实验研究
摘要
颗粒，评价了其对U87胶质瘤细胞的抗肿瘤效果。方法：将MPEG-COOH和胱胺通过EDC缩合得到MPEG-SS-NH2，再开环己内酯得到含有二硫键的两嵌段共聚物MPEG-SS-PCL，之后，通过常规的溶剂挥发法制备了载阿霉
素的纳米颗粒，评价了胶束的二硫键响应性能，紫外方法测定了胶束的载药率，体外观察了载药胶束的释放效率及
对U87胶质瘤细胞的抑制效果，最后采用Alamar Blue法检测纳米胶束对胶质瘤U87的细胞毒性作用。结果：载阿霉
素胶束形态均一，粒径小于50nm。在体外释放实验中，在高浓度谷胱甘肽（GSH）条件下，能快速释药。载药还
原响应胶束在胶质瘤细胞中也能较好的响应，并很好的释放出阿霉素，进一步的细胞毒性试验中，也证实了还原响
应胶束对胶质瘤细胞U87有很好的杀灭作用，其IC50值和裸药没有太大差异，而无响应的载药胶束则对U87没有太
大的杀灭作用。结论：应用具有二硫键响应的高分MPEG-SS-PCL能很好的包载阿霉素制备成胶束，因为粒径小于
50nm，能穿过血脑屏障。该载药胶束有很好的还原响应，体外试验中，该载药胶束在U87胶质瘤细胞能很好的响应
并释放出药物，同时，还原响应胶束对U87细胞有很好的治疗作用。
关键词
全文:
PDF参考
[1]Wang, Y. and T. Jiang, Understanding high grade
glioma: molecular mechanism, therapy and comprehensive
management. Cancer Lett, 2013. 331(2): p. 139-46.
[2]Talibi, S.S., B. Aweid, and O. Aweid, Prospective
therapies for high-grade glial tumours: A literature review.
Ann Med Surg (Lond), 2014. 3(3): p. 55-9.
[3]Farheen, M., et al., Harnessing Folate-Functionalized
Nasal Delivery of Dox-Erlo-Loaded Biopolymeric
Nanoparticles in Cancer Treatment: Development,
Optimization, Characterization, and Biodistribution Analysis.
Pharmaceuticals (Basel), 2023. 16(2).
[4]Madani, F., et al., Polymeric nanoparticles for
drug delivery in glioblastoma: State of the art and future
perspectives. J Control Release, 2022. 349: p. 649-661.
[5]姚鹏，et al.，跨血脑屏障复合功能纳米载体系统
的构建.中国医学科学院学报，2006.28（4）：p.481-485.
[6]周宓and王志强，跨血脑屏障药物转运的研究进
展.生命科学研究，2009.13（4）：p.370-376.
[7]曹远东and章龙珍，血脑屏障对颅内肿瘤综合
治疗影响的研究进展.徐州医学院学报，2005.25（3）：
p.267-270.
[8]Allhenn, D., M.A. Boushehri, and A. Lamprecht,
Drug delivery strategies for the treatment of malignant
gliomas. Int J Pharm, 2012. 436(1-2): p. 299-310.
[9]Gao, M., Y. Chen, and C. Wu, Size-dependent
chemosensitization of doxorubicin-loaded polymeric
nanoparticles for malignant glioma chemotherapy.
Bioengineered, 2021. 12(2): p. 12263-12273.
[10]Liu, J., et al., Enhanced anti-tumor activity of a drug
through pH-triggered release and dual targeting by calcium
phosphate-covered mesoporous silica vehicles. J Mater Chem
B, 2022. 10(3): p. 384-395.
[11]Sun, Z., et al., Application of dual targeting drug
delivery system for the improvement of anti-glioma efficacy
of doxorubicin. Oncotarget, 2017. 8(35): p. 58823-58834.
[12]Matsumura, Y., Preclinical and clinical studies of
NK012, an SN-38-incorporating polymeric micelles, which
is designed based on EPR effect. Adv Drug Deliv Rev, 2011.
63(3): p. 184-92.
[13]Maeda, H., G.Y. Bharate, and J. Daruwalla,
Polymeric drugs for efficient tumor-targeted drug delivery
based on EPR-effect. Eur J Pharm Biopharm, 2009. 71(3): p.
409-19.
[14]Hamaguchi, T., et al., NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend
in vivo antitumour activity and reduce the neurotoxicity of
paclitaxel. Br J Cancer, 2005. 92(7): p. 1240-6.
[15]Villa, F., R. Quarto, and R. Tasso, Extracellular
Vesicles as Natural, Safe and Efficient Drug Delivery Systems.
Pharmaceutics, 2019. 11(11).
[16]Fenart, L., et al., Evaluation of effect of charge and
lipid coating on ability of 60-nm nanoparticles to cross an
in vitro model of the blood-brain barrier. J Pharmacol Exp
Ther, 1999. 291(3): p. 1017-22.
[17]Schinkel, A.H., et al., P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and
pharmacological activity of many drugs. J Clin Invest, 1996.
97(11): p. 2517-24.
[18]Lockman, P.R., et al., Nanoparticle technology for
drug delivery across the blood-brain barrier. Drug Dev Ind
Pharm, 2002. 28(1): p. 1-13.
[19]Rawat, P.S., et al., Doxorubicin-induced
cardiotoxicity: An update on the molecular mechanism and
novel therapeutic strategies for effective management. Biomed
Pharmacother, 2021. 139: p. 111708.
[20]Wenningmann, N., et al., Insights into
Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms,
Preventive Strategies, and Early Monitoring. Molecular
Pharmacology, 2019. 96(2): p. 219-232.
[21]Batist, G., et al., Overexpression of a novel anionic
glutathione transferase in multidrug-resistant human breast
cancer cells. J Biol Chem, 1986. 261(33): p. 15544-9.
Refbacks
- 当前没有refback。
